Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Josh Benner"'
Autor:
Loren Lidsky, Shawn Hallinan, Josh Benner, Stephen Jones, Elise Smith, Patricia Houck, Heidi Stevenson, Don Yoder, Chronis Manolis, Allen Naidoo, Niteesh Choudhry, Chester B Good
BACKGROUNDThe Medicare Advantage (MA) program has grown rapidly over the past two decades, particularly among medically complex beneficiaries, which has implications for healthcare utilization, costs, and quality in the MA program. Ensuring safe and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97f05ede291d1f8ed3ccf82ab809840a
https://doi.org/10.1101/2023.04.12.23287952
https://doi.org/10.1101/2023.04.12.23287952
Autor:
Andrew M. Peterson, David P. Nau, Josh Benner, Femida Gwadry-Sridhar, Joyce A. Cramer, Michael B. Nichol
Publikováno v:
Value in Health. 10:3-12
The increasing number of retrospective database studies related to medication compliance and persistence (C&P), and the inherent variability within each, has created a need for improvement in the quality and consistency of medication C&P research. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1018fb47fbf8e5469ed3fafa0c1b3407
https://doi.org/10.1111/j.1524-4733.2006.00139.x
https://doi.org/10.1111/j.1524-4733.2006.00139.x
Autor:
Allan Gaw, Tom Walley, David A. Ganz, Joseph Jackson, A. Margot Lagaay, Philip S. Wang, Jerry Avorn, Sebastian Schneeweiss, Robert J. Glynn, Josh Benner, Ian Ford
Publikováno v:
Controlled Clinical Trials. 23:757-773
Little information exists to quantify the functional status and economic consequences of lipid-lowering therapy in elderly patients. We describe the design of the cost-effectiveness component of the first large, randomized, placebo-controlled trial o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10324d67aee5d9ba567b9be17feb2d8e
https://doi.org/10.1016/s0197-2456(02)00228-3
https://doi.org/10.1016/s0197-2456(02)00228-3
Publikováno v:
Thrombosis and haemostasis. 100(5)
SummaryA decision-analytic model incorporating a Markov process to assess the incremental cost and effectiveness of venous throm-boembolism (VTE) prevention strategies was used. Modeling was carried out using a hypothetical cohort of medical patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d7f4c0503f21964b708d66c481b820c
https://pubmed.ncbi.nlm.nih.gov/18989525
https://pubmed.ncbi.nlm.nih.gov/18989525
Autor:
Jerry, Avorn, Josh, Benner, Ian, Ford, David A, Ganz, Allan, Gaw, Robert J, Glynn, Joseph, Jackson, A Margot, Lagaay, Sebastian, Schneeweiss, Thomas, Walley, Philip S, Wang
Publikováno v:
Controlled clinical trials. 23(6)
Little information exists to quantify the functional status and economic consequences of lipid-lowering therapy in elderly patients. We describe the design of the cost-effectiveness component of the first large, randomized, placebo-controlled trial o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8696d7dca42a2db4917c90c42066675e
https://pubmed.ncbi.nlm.nih.gov/12505250
https://pubmed.ncbi.nlm.nih.gov/12505250
Publikováno v:
Blood. 110:1876-1876
Background: Hospitalized medical patients are at significant risk of venous thromboembolism (VTE). Although evidence-based guidelines exist which provide recommendations for thromboprophylaxis in hospitalized medical patients, the optimum regimen for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::289d5babbf868769b86b5c53cedd429b
https://doi.org/10.1182/blood.v110.11.1876.1876
https://doi.org/10.1182/blood.v110.11.1876.1876